RESUMEN

BACKGROUND AND OBJECTIVE: Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of Graves disease, occasionally severe and refractory to treatment, mainly in long-term disease. In these cases, one of the most important infiltrating cytokines in the orbital tissue is interleukin-6 (IL-6). METHODS: This is a case report, the methodology consisted of the application of tocilizumab in a patient with graves disease and the patient's follow-up. RESULTS: We present the case of a 54-year-old male with TAO who responded adequately to treatment with tocilizumab, an antibody directed against the IL-6 receptor. CONCLUSION: Tocilizumab could be an optional treatment in patients with TAO.

Asunto(s)

Anticuerpos Monoclonales Humanizados/uso terapéutico , Oftalmopatía de Graves/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Enfermedad Crónica , Oftalmopatía de Graves/diagnóstico , Oftalmopatía de Graves/inmunología , Humanos , Masculino , Persona de Mediana Edad , Inducción de Remisión , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X , Resultado del Tratamiento